Company Overview
Snapshot
Founded in August 2019 by Yair Feld, Cuspa operates with 1–10 employees. The company has raised $900K across two funding rounds. In March 2020, Cuspa secured seed funding from NGT3.
Business overview
Cuspa is a Health Tech & Life Sciences company developing an artificial cusp, called CUSPER, for the transcatheter treatment of aortic valve insufficiency (AI). This heart disorder involves the aortic valve not closing properly, leading to blood flowing backward into the heart. CUSPER is designed to be attached to the native aortic valve cusp using a nitinol grasper, aiming to preserve the functionality of a healthy aortic valve and prevent valve insufficiency. The company serves the healthcare industry, specifically focusing on cardiology and cardiovascular medical devices.
Strategic signal
In late 2022, news reports highlighted Cuspa's innovative device as a potential alternative to open-heart surgery for aortic valve repair. This indicates a strong market validation for minimally invasive solutions in cardiology and signals Cuspa's potential to disrupt traditional surgical approaches, offering a less invasive treatment option for patients with aortic valve insufficiency.
Log in to access full profile ›Company Intelligence Q&A
- What is Cuspa's core product?
- Cuspa's core product is CUSPER, an artificial cusp designed for the transcatheter treatment of aortic valve insufficiency. It attaches to the native aortic valve cusp using a nitinol grasper to restore proper valve function.
- When was Cuspa founded?
- Cuspa was founded in August 2019 by Yair Feld.
- What is Cuspa's current product development stage?
- Cuspa's CUSPER device is currently in the clinical trial stage, with pre-clinical studies on pigs having been carried out to optimize its performance.
- What is the primary medical condition Cuspa aims to address?
- Cuspa aims to treat aortic valve insufficiency (AI), a heart disorder where the aortic valve does not close properly, causing blood to flow backward into the heart.